Evaluating the safety of an anti-inflammatory medication called KAND567, and whether it can reduce heart damage in patients experiencing a heart attack.
A bit of background
Heart attacks are caused when one of the arteries supplying the heart becomes blocked. Current treatment for this involves a type of balloon being inserted to open the artery again and then a stent (small metal scaffold) is put in place to hold it open. This procedure is called an angioplasty.
Research has shown that opening the artery can cause inflammation in the heart, causing damage. This inflammation is generated by the immune system. A drug called KAND567 may be able to stop this inflammation by temporarily inhibiting the immune system.
The aim of this trial is to determine whether KAND567 can be used safely in heart attack patients and whether it does in fact stop inflammation in the heart.
How will we do this?
The aim is to recruit 60 or more eligible patients who have suffered a heart attack and who have agreed to have angioplasty treatment. The patients will be randomised into two groups.
One group will be treated with KAND567 and the other will be given a placebo (dummy drug).
The trial will investigate whether the size of the heart attack is reduced when patients are treated with KAND567 compared with patients who are treated with a placebo.
Watch our short video about the trial
Current status
Recruiting
Chief investigator
Ioakim Spyridopoulos, David Austin (PI)
Participating sites
Freeman Hospital Newcastle, South Tees University Hospitals NHS Foundation Trust.